Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Total 13F shares
-
185,173,982
-
Share change
-
+8,427,874
-
Total reported value
-
$6,405,659,795
-
Put/Call ratio
-
16%
-
Price per share
-
$34.57
-
Number of holders
-
302
-
Value change
-
+$325,204,584
-
Number of buys
-
187
-
Number of sells
-
107
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q1 2025
As of 31 Mar 2025,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
302 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
185,173,982 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, Kohlberg Kravis Roberts & Co. L.P., VANGUARD GROUP INC, BlackRock, Inc., JANUS HENDERSON GROUP PLC, Aisling Capital Management LP, STATE STREET CORP, FARALLON CAPITAL MANAGEMENT LLC, Capital Research Global Investors, and Frazier Life Sciences Management, L.P..
This page lists
302
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.